SparingVision

Paris, France

SparingVision is a biotechnology company developing genomic medicines for the treatment of blinding inherited retinal diseases.

Sep 2022

Series B

Biotechnology Health Care Life Science

Top Investors

BpifranceJeito Capital4BIO CapitalYsios CapitalIntellia Therapeutics

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about SparingVision

Who are SparingVision's investors?

SparingVision's investors include Bpifrance, Jeito Capital, 4BIO Capital, Ysios Capital, Intellia Therapeutics.

Where is SparingVision headquartered?

SparingVision is headquartered in Paris, France.

What does SparingVision do?

SparingVision is a biotechnology company developing genomic medicines for the treatment of blinding inherited retinal diseases.

What stage is SparingVision at?

SparingVision is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 14, 2022.

MLA

"SparingVision — Funding & Investors." VCBacked, September 14, 2022, https://www.vcbacked.co/company/sparingvision. Accessed July 1, 2026.

APA

VCBacked. (2022). SparingVision — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/sparingvision

Wikipedia (cite web)

{{cite web |title=SparingVision — Funding & Investors |url=https://www.vcbacked.co/company/sparingvision |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 14, 2022.

Similar Companies in Biotechnology

View all

Renaissance BioScience

Vancouver

Rapport Therapeutics

Boston

Neuroglee Therapeutics

Singapore

Living In Silico Inc.